New study findings show this risk was higher among children born prematurely or whose mother was classified as having low socioeconomic status.
Epilepsy should be added to the list of neurological outcomes following an infection of invasive Group B Streptococcus (iGBS)—particularly meningitis—in early infancy, new study results suggest.
Findings from a population-based cohort study, published in JAMA Network Open, revealed iGBS disease was linked with a higher incidence of epilepsy in later childhood, notably after meningitis. The risk of epilepsy in later childhood was higher among those born prematurely, males, or those born to a mother belonging to a low socioeconomic position (SEP).
iGBS disease is a leading cause of neonatal and young infant mortality around the world. In 2020, it was estimated that 500,000 cases of iGBS disease occurred within the first 3 months after birth, the authors wrote.
Although epilepsy has been reported as an outcome following iGBS disease, particularly meningitis, the risk of the condition after neonatal iGBS disease has yet to be investigated further, the researchers said. To address this knowledge gap, they studied children with iGBS born in Denmark between 1997 and 2017. Follow-up continued until the end of 2018.
A total of 1432 children with iGBS disease (sepsis, n = 1264; meningitis, n = 168) were included in the study and compared with 14,211 unaffected children. All participants were aged between 0 and 89 days, 55.3% were male, and nearly 79% had a gestational age of at least 37 weeks. The mother’s SEP was determined via income and education level.
Analyses revealed:
Overall, “we found a significantly higher risk of epilepsy in children with iGBS meningitis in later childhood compared with children not exposed to iGBS,” the authors wrote. “The risk of epilepsy for iGBS sepsis was not significant.”
Compared with those without iGBS, the cumulative incidence of epilepsy was higher within the first 5 years after diagnosis of iGBS.
To the authors’ knowledge, the study is the first to examine the long-term risk of epilepsy as an individual outcome after iGBS sepsis or meningitis.
The large cohort of children with iGBS disease and comparison group, in addition to long-term follow-up until adolescence, mark strengths of the current investigation. Researchers were also able to match groups on all matching variables with small differences between cohorts, helping to reduce residual confounding.
However, data for iGBS onset were defined based on admission date, meaning the study may have excluded iGBS infections from the day of birth. Results should also be interpreted with caution, due to the small size of the iGBS meningitis cohort, the authors noted. Data also did not account for childhood accidents, infectious diseases, or head trauma that took place after the index date.
“Our findings have implications for estimating the global burden of iGBS and should be considered in relation to the cost-effectiveness of interventions, such as intrapartum antibiotic prophylaxis and maternal vaccination,” the authors concluded. “Importantly, these data also have implications for affected individuals and underline the need for better long-term follow-up and care.”
Reference
Lykke MR, Sørensen HT, Lawn JE, Horváth-Puhó E. Long-term risk of epilepsy following invasive group B Streptococcus disease in neonates in Denmark. JAMA Netw Open. Published online April 21, 2023. doi:10.1001/jamanetworkopen.2023.9507
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More